- Rapid developments in genetic engineering and molecular biology is driving the market.
- High cost of vaccines is likely to hamper the market.
- Europe is expected to be the most lucrative recombinant vector vaccine market.
Recombinant vector vaccines are made through biological preparation that produce active immunity against certain microorganisms in human-beings and animals. They produce antibodies to fight with different types of bacteria and virus. The vaccine enables an antigen T-lymphocyte which in turn generates strong cell in the body that fight against antigen of microbes or virus. This combination of vaccine is effective as it is produced by DNA technology for the prevention of lethal disease. There is high demand of these vaccines due to the prevalent diseases such as swine flu, malaria, cancer, Zika virus, Ebola virus, among others. It is also a part of various research and development activities that are carried out to treat different types of cancers and tumors.
Recombinant vector vaccine generates good immune response against the microbes when compared to traditional vaccines. Therefore, it is increasingly preferred for the same, across the world. Rapid developments in genetic engineering and molecular biology is another factor facilitating the growth of the recombinant vector vaccines market. Although, high cost of vaccines is likely to hamper the market, growing technological advancements and awareness among people is expected to reduce the impact of the limitation during the forecast period.
Global Recombinant vector vaccines market is segmented on the basis of diseases, product type, end user, and region. On the basis of product, the global recombinant vector vaccines market can be segmented into attenuated recombinant vaccines, subunit recombinant vaccines, and vector recombinant vaccines. On the basis of disease type, the global recombinant vector vaccines market can be segmented into cancer, pneumococcal disease, Hepatitis B, DPT, influenza, and others. On the basis of the end user, the global recombinant vector vaccines market can be segmented into hospitals and clinics, adults, veterinary, pediatrics, and others. The veterinary sub-segment is further bifurcated into poultry and livestock. On the basis of region, the global recombinant vector vaccines market can be segmented into Europe, Asia Pacific, Middle East and Africa, South America and North America. Amongst all, Europe is expected to be the most lucrative recombinant vector vaccine market owing to favorable government initiatives and increasing demand in vaccine development in the region.
The key players operating in recombinant vector vaccines market are Johnson and Johnson, Serum Institute of India Private Limited, Daiichi Sankyo Inc., Emergent Bio Solutions Inc., Pfizer Inc., GlaxoSmithKline Plc., Abiomed Inc., Sanofi Pasteur SA, Mitsubishi Tanabe, and Pharma Corporation among others.